Wedbush Downgrades Aclaris Therapeutics to Neutral
Wedbush has downgraded Aclaris Therapeutics from Outperform to Neutral and reduced its price target for the company's stock.
Stocks · News reference
U.S. stock futures rise, Nasdaq 100 gains 200 points. Vipshop shares fall 4.9% after reporting Q2 earnings below expectations. Other stocks dip in pre-market trading.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wedbush has downgraded Aclaris Therapeutics from Outperform to Neutral and reduced its price target for the company's stock.
Omnicom Health Group received the 2026 Network of the Year award at the New York Festivals Health Awards.
Bond, a customer intelligence-driven engagement company, has acquired the creative and brand strategy agency EP+Co from Omnicom Group.
Gorilla Technology Group Inc. announced it will host a conference call on November 19, 2026, to discuss its financial results for the third quarter and nine months ended September 30, 2026.
Aclaris Therapeutics misses Phase 2 bosakitug endpoints but launches its Phase 2b modzatinib trial for moderate-to-severe lichen planus.